BAM
TCRT icon

Byrne Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Byrne Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-27
Closed -$3K – 628
2023
Q1 		$3K Hold
27
– – ﹤0.01% 521
2022
Q4 		$2.62K Buy
+27
New +$3.91K ﹤0.01% 479

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Byrne Asset Management's TCRT Position: Q2 2023 in Review

Byrne Asset Management sold out of Alaunos Therapeutics (TCRT) in Q2 2023, closing a stake of 27 shares — an estimated $3K sold.

Byrne Asset Management first reported a position in TCRT in Q4 2022 and held it in 2 quarters. The position peaked at $3K in Q1 2023. 100 funds tracked by Wall St. Rank hold TCRT as of Q2 2023.

  • Byrne Asset Management reported no remaining Alaunos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Byrne Asset Management sold 27 Alaunos Therapeutics shares in Q2 2023, an estimated $3K.
  • Byrne Asset Management first reported a position in Alaunos Therapeutics in Q4 2022 and held it in 2 quarters.
  • Byrne Asset Management's Alaunos Therapeutics position peaked at $3K in Q1 2023.
  • 100 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2023.

Based on Byrne Asset Management's 13F filing for Q2 2023, filed 21 Jul 2023.